96 related articles for article (PubMed ID: 8390739)
1. Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis.
Kizilisik TA; Preiksaitis JK; Kneteman NM
Transplant Proc; 1993 Jun; 25(3):2282-3. PubMed ID: 8390739
[No Abstract] [Full Text] [Related]
2. Incidence and therapy of cytomegalovirus disease after liver transplantation.
Wiens M; Lefèbre B; Blumhardt G; Schmidt CA; Lohmann R; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1985-6. PubMed ID: 8385829
[No Abstract] [Full Text] [Related]
3. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients.
Saliba F; Eyraud D; Samuel D; David MF; Arulnaden JL; Dussaix E; Mathieu D; Bismuth H
Transplant Proc; 1993 Feb; 25(1 Pt 2):1444-5. PubMed ID: 8382876
[No Abstract] [Full Text] [Related]
5. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
[No Abstract] [Full Text] [Related]
6. Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir.
Nakazato PZ; Burns W; Moore P; Garcia-Kennedy R; Cox K; Esquivel C
Transplant Proc; 1993 Apr; 25(2):1935-7. PubMed ID: 7682357
[No Abstract] [Full Text] [Related]
7. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
Reddy SP; Handa A; Tan L; Devaney A; Hughes D; Mason P; Friend PJ; Darby CR
Transpl Int; 2003 Oct; 16(10):726-9. PubMed ID: 12827230
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cytomegalovirus disease in heart transplant recipients by prophylaxis with cytomegalovirus hyperimmune globulin plus oral acyclovir.
Eisenmann D; Knipp H; Laube H; Stegmann T
Transplant Proc; 1990 Oct; 22(5):2322-3. PubMed ID: 2171169
[No Abstract] [Full Text] [Related]
9. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
Uber L; Cofer J; Baliga P; Rajagopalan PR
Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
[No Abstract] [Full Text] [Related]
10. [Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients].
Moreno J; Montero JL; Gavilán F; Costán G; Herrero C; Cárdenas M; Sánchez-Guijo P; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 1999 Oct; 17(8):382-5. PubMed ID: 10563084
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis.
Green M; Reyes J; Nour B; Beatty D; Kaufman M; Wilson J; Todo S; Tzakis A
Transplant Proc; 1994 Feb; 26(1):173-4. PubMed ID: 8108926
[No Abstract] [Full Text] [Related]
12. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus disease in liver transplant recipients.
Jeng LB; Lee WC; Wang CC; Wang KL; Chen SC; Chen MF; Chien RN; Chiu CT; Lin DY; Tan PP
Transplant Proc; 1994 Aug; 26(4):2227-8. PubMed ID: 8066727
[No Abstract] [Full Text] [Related]
14. Ganciclovir/acyclovir prophylaxis reduces the incidence of cytomegalovirus infections in pancreas transplant recipients.
Harland RC; Vernon WB; Bunzendahl H; Thompson JK; Lawrence C; Bollinger RR
Transplant Proc; 1994 Apr; 26(2):432-3. PubMed ID: 8171488
[No Abstract] [Full Text] [Related]
15. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.
Carrieri G; Jordan ML; Shapiro R; Scantlebury VP; Vivas C; Kusne S; Magnone M; McCauley J; Starzl TE
Transplant Proc; 1995 Feb; 27(1):961-3. PubMed ID: 7879246
[No Abstract] [Full Text] [Related]
16. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus infections and liver transplantation: an overview.
Balfour HH; Heussner RC
Transplant Proc; 1993 Apr; 25(2):2012-3. PubMed ID: 8385830
[No Abstract] [Full Text] [Related]
18. Special considerations regarding CMV in lung transplantation.
Avery RK
Transpl Infect Dis; 1999; 1 Suppl 1():13-8. PubMed ID: 11565581
[TBL] [Abstract][Full Text] [Related]
19. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
[TBL] [Abstract][Full Text] [Related]
20. Acyclovir to prevent cytomegalovirus infection in renal-graft recipients.
Grundy JE; Griffiths PD
N Engl J Med; 1989 Nov; 321(18):1268-9. PubMed ID: 2552315
[No Abstract] [Full Text] [Related]
[Next] [New Search]
